My HCV patient is co-infected with HIV: how to manage?
|
|
- Michael Stevens
- 6 years ago
- Views:
Transcription
1 EASL «White Nights of Hepatology 2016» My HCV patient is co-infected with HIV: how to manage? A.V. Кravchenko MD, Professor Russia AIDS Federal Center Central Research Institute of Epidemiology St.-Petersburg, June 2, 2016
2 The proportion of patients with HIV infection in the Russian Federation who have a diagnosis of chronic hepatitis C and / or B 50,00% 40,00% 30,00% 20,00% 10,00% 39,40% 40,90% 36,80% 36,80% 35,50% 34,90% 27,80% 0,00% % of the patients have a diagnosis of hepatitis C who are under medical supervision. In gg. from end-stage liver disease died patients with HIV infection in Russia. Chronic viral hepatitis treatment received 12.1% of the patients. А.V. Kravchenko et al., 5 ЕЕСААС, 2016, Abstract book, P According to the registration form 61
3 Distribution HIV-infected patients of HCV genotypes 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 58 55, ,4 41,4 Genotype 3 Genotype 2 Genotype 1 V.G. Kanestry, A.V. Kravchenko et al. Epidemiology and Infectious diseases, 2001; 1: A.V. Kravchenko et al. 4 Russian Congress of Infectious diseases, J. Infectious diseases,2012; Suppl.1 (10):
4 HCV/HIV Coinfection: Who to Treat? All HCV/HIV coinfected patients are candidates for HCV therapy For most HIV/HCV-coinfected patients, including those with cirrhosis, the benefits of ART outweigh concerns regarding drug-induced liver injury Although older antiretroviral drugs have been associated with higher rates of hepatotoxicity in patients with chronic HCV infection, newer antiretroviral agents currently in use appear to be less hepatotoxic Consider comorbid conditions that limit life expectancy or increase the risks associated with HCV therapy Recommended initial ART regimens for most HCV/HIVcoinfected patients are the same as those recommended for individuals without HCV infection HIV disease must be stable before initiating HCV therapy AASLD/IDSA. HCV Management (February 24, 2016). DHHS. Revision January 26, 2016.
5 Management of Persons with Chronic HCV/HIV Co-infection Chronic HCV/HIV Perform FibroScan and/or serum marker and/or liver biopsy F0/F1 F2-F4 HCV treatment can be Considered HCV treatment Is Recommended Guidelines of European AIDS Clinical Society, Version 8.0. October 2015
6 Proportion Free From Event (%) SVR Associated With Decreased Morbidity, Mortality in HIV/HCV Pts Retrospective analysis of 695 HIV/HCV-coinfected pts treated with IFN/RBV between 1/2000-1/2008 in 19 centers in Spain Median follow-up (IQR): No SVR: 59.3 mos ( ) SVR: 59.5 mos ( ) SVR significantly associated with decreased overall mortality and secondary liver outcomes SVR No SVR P = P =.024 Overall mortality Liver-related mortality P = P <.001 Liver decompensation Liver-related events Follow-up (Mos) Berenguer J, et al. ICAAC Abstract H Reproduced with permission.
7 Proposed Optimal Duration of Dual HCV Therapy in Persons with Chronic HCV/HIV Co-infection Not Eligible for Triple Therapy Including DAAs against HCV Guidelines of European AIDS Clinical Society, Version 8.0. October 2015
8 Rate SVR (%) in HCV/HIV Co-infection patients by Genotype HCV (mitt-analisys) Genotypes 2/3 62,16 77,78 Genotype 1 36,36 52,9 All genotypes 50 65, % PegIFN CePegIFN F.I. Nagimova et al. Infectious diseases, 2016; 1(14): 5-13.
9 80 SVR according to rs genotype IL28 in HIV/HCV co-infected patients with G1 HCV (mitt-analisys) 75% ,8% 55,6% ,22% 30% 25% 10 0 CePegIFN PegIFN С/С С/Т Т/Т F.I. Nagimova et al. Infectious diseases, 2016; 1(14): 5-13.
10 SVR24, % Naïve Patients with HCV genotype G1, that can be successfully treated with dual therapy The distribution of predictors in accordance with the pre-treatment and RVR RVR IL28B non-cc RVR IL28B CC No RVR RNA HCV IU/ml RNA HCV < IU/ml RNA HCV IU/ml RNA HCV < IU/ml Patients therapy with PegIFN alpha 2a or alpha 2b + RBV. Andriulli A, et al. J Hepatol 2014; 60: 16 21
11 Multiple Classes of Direct-Acting Anti-НСV Agents NS3 Protease Inhibitors Telaprevir Boceprevir Simeprevir Asunaprevir Paritaprevir Narlaprevir* Danoprevir* Sovaprevir* Grazoprevir* NS5A Replication Complex Inhibitors Daclatasvir Ledipasvir* Ombitasvir Elbasvir* Velpatasvir* NS5B-Polymerase NUC Inhibitors Non-NUC Inhibitors Sofosbuvir Dasabuvir Beclabuvir* Lomibuvir* Setrobuvir* -previr -asvir -buvir * Non registration in Russia
12 HCV Treatment Options in HIV/HCV Co-infected Persons Guidelines of European AIDS Clinical Society, Version 8.0. October 2015
13 HCV Treatment Options in HIV/HCV Co-infected Persons Guidelines of European AIDS Clinical Society, Version 8.0. October 2015
14 SVR12 (%) Study 212: SVR12 rates in HIV/HCV coinfected patients G1 treated with SMV/PR p< SMV/PR Historic PR-only control p< * /53 51/176 16/28 2/37 Naïves 5 Non-responders *From PEGASYS USPI, co-infected patients; from INCIVEK USPI, mono-infected patients Dieterich D, et al. EACS Abstract LBPS9/5
15 Patients (%) TURQUOISE-I: SVR12 rates Ombitasvir/ Paritaprevir/r + Dasabuvir + RBV in HCV Genotype 1 With HIV Co-infection ,5 90,6 29/31 29/32 12 weeks 24 weeks The SVR12 rates in the 12- and 24- week arms was 93,5% (29/31) and 90,6% 929/32), respectively The SVR12 was 91.1% in patients with GT1a and 100% - GT1b Safety No treatment-emergent serious adverse events or discontinuations due to adverse events RBV dose reduction (n=6, all achieved SVR) Most common adverse events Fatigue, insomnia, nausea, headache Wyles D et al. Presented at the 65th Annual Meeting of the AASLD, November 7-11, 2014, Boston, Massachusetts. Poster
16 SVR12 (%) TURQUOISE-I: Efficacy (ITT) and Resistance Results n/n = 12 wks (n = 31) 24 wks (n = 32) * 29/ 31 29/ 32 15/ 16 12/ 12 Overall Atazanavir Raltegravir *2 pts in 24-wk arm had HCV viremia recurrence suspected to be caused by HCV reinfection. Eron JJ, et al. Glasgow HIV Abstract O222. Reproduced with permission. 14/ 15 17/ 20 VF with RAVs in all 3 HCV target genes occurred in 2 pts with genotype 1a HCV, previous null response to pegifn/rbv, and cirrhosis VF (posttreatment) without RAVs occurred in 2 HCV treatment-naive pts with genotype 1a HCV Genetic analysis strongly supported HCV reinfection with different isolate Both pts MSM who reported highrisk sexual practices posttreatment
17 SVR12, % ALLY-2: Virologic Outcomes With SOF + DCV in HIV/HCV-Coinfected Pts High SVR12 rates with 12 wks SOF + DCV n/n = 0 Large decline in SVR rate with shortening to 8 wks 96 80/ Wk GT Overall / 43/ 98/ 38/ 51/ Wk 12-Wk 12-Wk 8-Wk 12-Wk Naive Exp d Naive Exp d In 12-wk groups analyzed by GT, 100% with SVR12 except GT1a GT1a naive: 96%; exp d: 97% Similar SVR12 rates in pts with or without baseline NS5A RAVs 12 pts with relapse, 10 in 8-wk arm 1 in 8-wk arm had emergent NS5A RAVs No NS5B RAVs at BL or time of failure No discontinuation of therapy due to AEs 10 pts with HIV-1 RNA > 50 at EOT 8 with repeat testing; 7 with suppression without change in ART; 1 with HIV-1 RNA of 59; 2 LTFU 2 with HIV VF = HIV-1 RNA 400 c/ml Wyles DL, et al. CROI Abstract 151LB. Reproduced with permission.
18 SVR12 Patients (%) Study HALLMARK-DUAL Daclatasvir + Asunaprevir: SVR Treatment naive Null/Partiall responders IFN ineligible/intolerant Breakthrough: 9 (4%) treatment naive, 26 (13%) nonresponders, 20 (9%) IFN ineligible/intolerant Relapse: 5 (3%) treatment naive, 7 (4%) nonresponders, 12 (6%) IFN ineligible/intolerant Serious AEs* occurred in 6% treatment-naive pts, 5% nonresponders and 7% IFN ineligibleintolerant pts AE leading to discontinuation in 3%, 1% and 1%, respectively Manns M., Pol S., Jacobson I. et al. Lancet, 2014
19 SVR12 (%) ION-4 Study: SVR12 Rates for Ledipasvir/Sofosbuvir in HIV/HCV Coinfection % 95% 97% 96% 94% Relapse (n=10) Overall (n=335) HCV Treatment Naïve (n=150) HCV Treatment Experienced (n=185) No Cirrhosis (n=268) Cirrhosis (n=67) No impact on SVR12 rate: gender, HCV genotype, baseline HCV RNA, IL28B genotype, cirrhosis, prior HCV treatment, ART regimens, and baseline CD4 count. Lower SVR12 rate observed among black patients (90%). Naggie S, et al. 22 nd CROI. Seattle, Abstract 152LB.
20 SVR12 (%) C-EDGE Co-infection: Key Findings n/n = 0 SVR12 With 12 Wks GZR/EBV According to Genotype / / / 44 27/ 28 All Pts GT1a GT1b GT4 Discontinued* Relapse Reinfection No subgroup provided efficacy advantage or disadvantage, including ART regimen New NS3, NS5A RAVs detected at failure in 4 of 5 pts who relapsed Short-lived HIV-1 RNA increases in 2 pts on ART during GZR/EBV treatment Both resuppressed HIV-1 RNA without change of ART During GZR/EBV Tx, no significant changes in CD4+ cell count GZR/EBV well tolerated: no pt discontinued for AEs and no serious treatment-related AEs *Unrelated to virologic failure. Rockstroh JK, et al. IAS Abstract TUAB0206LB. Rockstroh JK, et al. Lancet HIV. 2015;2:e319-e327. Reproduced with permission.
21 Pts With Potential Drug Interactions (%) How Frequent Are Significant Interactions Between HCV DAAs and ART? Retrospective analysis of pts with HIV/HCV coinfection (n = 125) 81% receiving TDF, 35% RAL, 16% EFV, 40% PI/RTV Drug interactions None Moderate Severe SMV + SOF LDV/SOF DCV + SOF OBV/PTV/R TV + DSV Langness J. HIV and Hep Clin Pharm Workshop Abstract 18.
22 HIV/HCV Drug Drug Interactions SMV + SOF LDV/SOF DCV + SOF OBV/PTV/RTV + DSV EBR/GZR Atazanavir + RTV Darunavir + RTV Lopinavir/RTV Tipranavir + RTV Efavirenz Rilpivirine Etravirine Dolutegravir or raltegravir Elvitegravir + COBI Abacavir/lamivudine * Maraviroc Tenofovir alafenamide Tenofovir DF/ emtricitabine nephrotoxicity No clinically significant interaction expected Potential interaction may require adjustment to dosage, timing of administration, or monitoring Do not coadminister Adapted from AASLD/IDSA. HCV guidelines. March 2016
23 AASLD/IDSA Guidance for HIV/HCV Co-infection Same recommendations as in HCV-monoinfected pts Main consideration is drug drug interactions between ART and HCV therapy Need to adjust or withhold RTV if receiving a boosted PI with OBV/PTV/RTV + DSV Potential for LDV-mediated increase in tenofovir levels, especially if tenofovir used with RTV-boosted PIs Avoid LDV with tenofovir if CrCl < 60 ml/min or if receiving tenofovir with RTV Other interactions at: aidsinfo.nih.gov/guidelines, hiv-druginteractions.org, hep-druginteractions.org AASLD/IDSA. HCV Management (February 24, 2016).
24 Changing ARV regime before the start of the treatment of Chronic Hepatitis C scheme with HCV PI Before the start of therapy of CHC patients already receiving effective ART (HIV RNA <50 copies/ml; CD4 + lymphocytes > 100 cells/mm 3 ): The treatment regimen of HIV infection (without reducing the effectiveness of ART) can be changed for the duration of the use of PI HCV (12 weeks of TVR and SMV, weeks for OMV/PTV/RTV, 44 weeks - for BOC). PI HIV (except ATV/r in combination with TVR and ATV combined with OMV / PTV / RTV) can at this time be replaced by RAL and, probably, DTG (coupled with BOC, TVR, SMV and OMV / PTV / RTV) or RPV (coupled with BOC, TVR or SMV), ETR (coupled with BOC or TVR). When used in ART mode drugs NVP or EFV changing the therapeutic regimen should be performed at least 1 week prior to initiation of therapy of CHC After the end of the treatment period, HCV PI can revert to the original regime of ART Protocols of follow-up and treatment of patients with HIV infection. Epidemiology and Infectious Diseases, 2015, 6, Supplement
Antiviral treatment in Unique Populations
Antiviral treatment in Unique Populations Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Unique HCV Populations HIV/HCV co-infected
More informationHIV-HCV coinfection. Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland
HIV-HCV coinfection Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland Disclosures Principal investigator for research grants Funds paid to Johns Hopkins
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationGlobal Prevalence of HBV, HCV, HIV
Treatment of Patients with HCV and HIV Paul Y. Kwo, MD, FACG Professor of Medicine Stanford University email: pkwo@stanford.edu Global Prevalence of HBV, HCV, HIV 24 m Journal of Clinical Virology Page
More informationHIV and Hepatitis C Have we finally slayed the beast?
HIV and Hepatitis C Have we finally slayed the beast? Mark W. Sonderup Division of Hepatology Department of Medicine University of Cape Town & Groote Schuur Hospital Accelerated Fibrosis in HIV-HCV co-infected
More informationManagement of HIV/HCV Coinfection. Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY
Management of HIV/HCV Coinfection Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY Disclosure Dr. Marks has received grants and research support from Gilead Sciences
More informationLearning Objective. After completing this educational activity, participants should be able to:
Learning Objective After completing this educational activity, participants should be able to: Use patient characteristics and preferences to select HCV treatment strategies that maximize the potential
More informationDirect-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD
Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD The HCV Lifecycle: Multiple Targets Polymerase Inhibitors Protease Inhibitors NS5A Inhibitors
More informationHIV-HCV Co-Infection in Shobha Swaminathan, MD Associate Professor of Medicine Rutgers New Jersey Medical School
HIV-HCV Co-Infection in 2018 Shobha Swaminathan, MD Associate Professor of Medicine Rutgers New Jersey Medical School AASLD/IDSA and DHHS Guidance: HIV/HCV Coinfection All pts with HIV should be screened
More informationBaseline and acquired viral resistance to DAAs: how to test and manage
Baseline and acquired viral resistance to DAAs: how to test and manage Round table discussion by Marc Bourliere, Robert Flisiak, Vasily Isakov, Mark Sulkowsky & Konstantin Zhdanov Prevalence of baseline
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationHIV/HCV Coinfection: Why It Matters and What To Do About It. Cody A. Chastain, MD 10/26/16
HIV/HCV Coinfection: Why It Matters and What To Do About It Cody A. Chastain, MD 10/26/16 Disclosures I have no relevant financial disclosures. Objectives At the end of this lecture, the learner will be
More informationSeparate clinical trials for HIV- HCV coinfected patients are NOT a necessity. Patrick Ingiliz, Berlin
Separate clinical trials for HIV- HCV coinfected patients are NOT a necessity Patrick Ingiliz, Berlin Back in the days when HCV genotype 1 was the problem SVR (%) 100 90 80 70 60 50 40 30 20 10 0 35% PRESCO
More informationWonder pills, breakthroughs and continuing challenges HIV and Hepatitis C antiviral treatments revisited
Wonder pills, breakthroughs and continuing challenges HIV and Hepatitis C antiviral treatments revisited Harald Hofer Department of Internal Medicine III Division of Gastroenterology and Hepatology Medical
More informationHCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London
HCV Resistance Clinical Aspects Sanjay Bhagani Royal Free Hospital/UCL London DAAs in 2018, and beyond % patients % patients Changing characteristics of patients treated with DAA over time Prospective,
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationNew York State HCV Provider Webinar Series. Treatment of HCV/HIV Co-Infection
New York State HCV Provider Webinar Series Treatment of HCV/HIV Co-Infection Objectives Review the epidemiology of HCV and HIV/HCV co-infection Discuss the burden of HIV/HCV co-infection Discuss the treatment
More informationGenotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty
Genotype 1 HCV in 216: Clinical Decision Making in a Time of Plenty Ira M. Jacobson, MD Chair, Department of Medicine Mount Sinai Beth Israel Senior Faculty and Vice-Chair, Department of Medicine Icahn
More informationTreating Hepatitis C-HIV Coinfected Patients Welcome to the Real World
Treating Hepatitis C-HIV Coinfected Patients Welcome to the Real World H. Nina Kim, MD MSc Associate Professor of Medicine University of Washington Division of Allergy & Infectious Diseases April 21, 2017
More informationWhat is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago
What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate
More informationHCV Treatment of Genotype 1: Now and in the Future
HCV Treatment of Genotype 1: Now and in the Future Bruce R. Bacon, MD, FACG James F. King, MD Endowed Chair in Gastroenterology Professor of Internal Medicine Co-Director of the Abdominal Transplant Program
More informationCan a One-Size-Fits-All Approach Be Applied to All Treatment-Naïve GT1 HCV Patients?
Can a One-Size-Fits-All Approach Be Applied to All Treatment-Naïve GT1 HCV Patients? Ira M. Jacobson, MD Vincent Astor Distinguished Professor of Medicine Chief, Division of Gastroenterology and Hepatology
More informationICVH 2016 Oral Presentation: 28
Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients A Luetkemeyer 1, C Cooper 2, P Kwo 3, K
More informationHepatitis C Medications Prior Authorization Criteria
Hepatitis C Medications Authorization Criteria Epclusa (/velpatasvir), Harvoni (ledipasvir/), Sovaldi (), Daklinza (daclatasvir), Zepatier (elbasvir/grazoprevir), Olysio (simeprevir), Viekira Pak (ombitasvir/paritaprevir/ritonavir;
More informationKristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York
Newly Approved Hepatitis C Virus Drugs: Approach to Initial Therapy Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York Learning Objectives After attending this presentation,
More informationHCV In 2015: Maximizing SVR
HCV In 2015: Maximizing SVR Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia ramji_a@hotmail.com Disclosures (within Last
More informationUpdate on the Treatment of HCV
Update on the Treatment of HCV K. Rajender Reddy, MD Professor of Medicine Director of Hepatology Director, Viral Hepatitis Center University of Pennsylvania Philadelphia, USA 1 K. Rajender Reddy, MD Disclosure
More informationInitial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona
Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives
More informationDebate: Do We Need More HCV Drugs Con Standpoint
Debate: Do We Need More HCV Drugs Con Standpoint 18 th Antivirals PK Workshop, Friday 16 th June 2017, Chicago Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany Conflict
More informationHIV/HCV Co-Infection
HIV/HCV Co-Infection 2015 Kentucky Conference on Viral Hepatitis Matt Cave, M.D. Associate Professor Department of Medicine Division of Gastroenterology, Hepatology, & Nutrition Department of Pharmacology
More informationPotential Issues in Treating HIV/HCV co-infection with new HCV antivirals
State of the Art in Hepatitis C Virus Infection in HIV/HCV-Coinfected Patients FORMATTED: 11/17/15 David L. Wyles, MD Associate Professor of Medicine University of California San Diego San Diego, California
More informationTreatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona
Treatement Experienced patients without cirrhosis Rafael Esteban Hospital Universitario Valle Hebron Barcelona Agenda With IFN PegIFN+ Ribavirin + Simeprevir PegIFN+ Ribavirin+ Sofosbuvir Without IFN Sofosbuvir
More informationUpdate on chronic hepatitis C treatment: current trends, new challenges, what next?
Update on chronic hepatitis C treatment: current trends, new challenges, what next? Matti Maimets 12.06.2015 MMaimets15 Disclosure this presentation is sponsored by Gilead Sciences MMaimets15 MMaimets15
More informationCurrent trends in CHC 1st genotype treatment
Current trends in CHC 1st genotype treatment Tarik Asselah MD, PhD Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France Disclosures Employee of Paris Public University
More informationTreatments of Genotype 2, 3,and 4: Now and in the future
Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve
More informationNew Antivirals for Hep C in Context of HIV: Vosevi and Mavyret
New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret John Scott, MD, MSc, FIDSA November 16, 2017 This presentation is intended for educational use only and does not in any way constitute medical
More informationDr Janice Main Imperial College Healthcare NHS Trust, London
BHIVA AUTUMN CONFERENCE 2014 Including CHIA Parallel Sessions Dr Janice Main Imperial College Healthcare NHS Trust, London 9-10 October 2014, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationAdvances in the all oral HCV DAA to treat HCV/HIV: No longer a special population? Josep Mallolas Hospital Clínic-University of Barcelona
Advances in the all oral HCV DAA to treat HCV/HIV: No longer a special population? Josep Mallolas Hospital Clínic-University of Barcelona HCV in HIV/HCV: No longer a special population? HIV/HCV epidemiology
More information1/16/2019. Goals of HCV Therapy. Objectives. Treating Hepatitis C and HIV Co Infection. Cure Defined as sustained virologic response (SVR)
HCV ECHO WESTERN STATES HCV ECHO WESTERN STATES Treating Hepatitis C and HIV Co Infection Paulina Deming, Pharm D Associate Professor, College of Pharmacy Assistant Director, Viral Hepatitis Programs,
More informationRome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING
Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN
More informationHCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London
HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London European HIV Hepatitis Co-infection Conference QEII Conference Centre 10 th December 2015 Dr Ashley Brown
More informationEvolution of Therapy in HCV
Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR
More informationViva La Revolución: Options to Combat Hepatitis C
Viva La Revolución: Options to Combat Hepatitis C David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After attending
More informationThe HCV Pipeline Ira M. Jacobson, MD, FACP, FACG, AGAF. Slide Presentation. IFN-free DAA combinations (G1)
Slide Presentation The HCV Pipeline Vincent Astor Distinguished Professor of Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the Study of Hepatitis C Weill Cornell
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More informationAASLD/IDSA HCV treatment guidelines. Arthur Y. Kim, MD Massachusetts General Hospital Harvard Medical School
AASLD/IDSA HCV treatment guidelines Arthur Y. Kim, MD Massachusetts General Hospital Harvard Medical School Disclosure Statement for Arthur Kim Grant/research support to institution, last 12 months: Gilead
More informationCurrent Management of Hepatitis C Virus Infection
Current Management of Hepatitis C Virus Infection Kristen M. Marks, MD Assistant Professor Weill Cornell Medicine New York, New York FORMATTED: 10/13/16 Financial Relationships With Commercial Entities
More informationHCV/HIV Coinfection ANTON AND MARGARET FUISZ CHAIR IN MEDICINE. HIV and HCV Share Risk Factors PREVALENCE OF CO-INFECTION BY RISK FACTOR 60%
HCV/HIV Coinfection BRUCE A. LUXON, MD, PHD, FACG ANTON AND MARGARET FUISZ CHAIR IN MEDICINE PROFESSOR AND CHAIRMAN DEPARTMENT OF MEDICINE GEORGETOWN UNIVERSITY HIV and HCV Share Risk Factors PREVALENCE
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationTransformation of Chronic Hepatitis C Treatment
Transformation of Chronic Hepatitis C Treatment UVHS, Adana, 22 May 2015 Christoph Sarrazin Goethe-University Hospital Frankfurt am Main Germany Epidemiology of HCV Infection Global Global HCV Prevalence
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More informationTreatment of chronic hepatitis C in HIV co-infected patients
Treatment of chronic hepatitis C in HIV co-infected patients Vicente Soriano Department of Infectious Diseases Hospital Carlos III, Madrid, Spain The most prevalent chronic viral infections in humans HBV
More informationCase. 63 year old woman now with:
Case 63 year old woman now with: HCV GT 1b, HCV RNA 6.2 x 10 6 IU/mL Asymptomatic except for fatigue Normal exam ALT 72 IU/mL, Bili 0.9 mg/dl, INR 1.1, Albumin 3.9 g/dl, Creatinine 0.7 mg/dl Normal EGD
More information5/2/2016. Andrew I. Aronsohn, MD Associate Professor of Medicine University of Chicago Chicago, Illinois. Learning Objectives
Challenges in the Management and Treatment of HIV/Hepatitis C Virus Coinfection Andrew I. Aronsohn, MD Associate Professor of Medicine University of Chicago Chicago, Illinois FORMATTED: 05/02/2016 Chicago,
More informationCurrent State of Treatment for HCV. Nancy Reau, MD Associate Professor of Medicine University of Chicago
Activity Code FA376 Current State of Treatment for HCV Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives Upon completion of this presentation, learners should be
More information8/5/2014. A new era of HCV clinical management. Direct-Acting Antivirals for Hepatitis C. Goal of HCV treatment is viral cure HIV HBV HCV
NS5B NS5B 8/5/214 A new era of HCV clinical management Mark Sulkowski, MD Professor of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Disease and Gastroenterology/Hepatology
More informationHepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More informationCCO Official Conference Coverage: Clinical Impact of New Data From AASLD 2015
CCO Official Conference Coverage: Clinical Impact of New Data From AASLD 2015 CCO Official Conference Coverage of the 2015 Annual Meeting of the American Association for the Study of Liver Diseases, November
More informationHepatitis Mini-Symposium Johns Hopkins Brazil Conference HIV/AIDS
Hepatitis Mini-Symposium Johns Hopkins Brazil Conference HIV/AIDS April 15, 2016 Ashwin Balagopal, M.D. and Michael Chattergoon, M.D./Ph.D. Division of Infectious Diseases Center for Viral Hepatitis Research
More informationNS5A inhibitors: ideal candidates for combination?
NS5A inhibitors: ideal candidates for combination? Professor Vasily Isakov, MD, PhD, AGAF Dep.Gastroentrology & Hepatology, ION, Russian Academy of Sciences, Moscow Structure and function of NS5A Meigang
More informationIFN-free therapy in naïve HCV GT1 patients
IFN-free therapy in naïve HCV GT1 patients Paris Hepatitis Conference Paris, 12th January, 2015 Pr Tarik Asselah MD, PhD; Service d Hépatologie & INSERM U773 University Paris Diderot, Hôpital Beaujon,
More informationInitial Treatment of the Hepatitis C Virus-Infected Patient
IDSA/AASLD www.hcvguidelines.org http://www.easl.eu/research/our-contributions/clinical-practice-guidelines/detail/easl-recommendations-ontreatment-of-hepatitis-c-216 Initial Treatment of the Hepatitis
More informationCases: Management of Hepatitis C in Prior Treatment Failure
Cases: Management of Hepatitis C in Prior Treatment Failure David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationTough Cases in HIV/HCV Coinfection
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Tough Cases in HIV/HCV Coinfection John Scott, MD, MSc Assistant Professor University of Washington Presentation prepared by: J Scott Last Updated: Jun 5, 2014
More informationHCV Treatment Options in 2017/2018: What s Here and What s Coming Soon
HCV Treatment Options in 2017/2018: What s Here and What s Coming Soon Supported by educational grants from AbbVie; Bristol-Myers Squibb; Gilead Sciences; Janssen Therapeutics; Merck & Co., Inc; and ViiV
More informationHCV in 2017: New Therapies and New Opportunities. Presentation prepared by: Date prepared: OBJECTIVES
Project ECHO HCV Collaborative HCV in 217: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College of Pharmacy University
More informationSaeed Hamid, MD Alex Thompson, MD, PhD
Saeed Hamid, MD Alex Thompson, MD, PhD 1 We will review some top line data from EASL Majority of the time discussing how the data affects daily practice 2 Grazoprevir (GZR; MK-5172) + Elbasvir (EBR; MK-
More informationKeynote Lecture: Optimal Management of HCV-HIV Coinfection
THASL Annual Meeting 2015 Keynote Lecture: Optimal Management of HCV-HIV Coinfection 26 February 2015 Prof. Chutima Pramoolsiansap Today s Talk HIV/HCV-coinfection Background and epidemiology When to start
More informationHepatitis C in Special Populations
Hepatitis C in Special Populations David E. Bernstein, MD, FACG Vice Chairman of Medicine for Clinical Trials Chief, Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases Northwell Health
More informationHepatitis C Virus Management
Hepatitis C Virus Management FORMATTED: 04/20/17 New York, New York: February 24, 2017 Marion G. Peters, MD John V. Carbone, Endowed Chair Professor of Medicine University of California San Francisco San
More informationEASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor
More informationTreatment of Patients with HCV and HIV
Treatment of Patients with HCV and HIV BRUCE A. LUXON, MD, PHD, FACG ANTON AND MARGARET FUISZ CHAIR IN MEDICINE PROFESSOR AND CHAIRMAN DEPARTMENT OF MEDICINE GEORGETOWN UNIVERSITY Four Questions Is HIV/HCV
More informationTreatment of hepatitis C today and tomorrow Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S., University of Palermo, Italy
Treatment of hepatitis C today and tomorrow Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S., University of Palermo, Italy antonio.craxi@unipa.it Ad Board and grants: Abbvie, Achillion, BristolMyers Squibb,
More informationManagement of HCV in Prior Treatment Failure
Management of HCV in Prior Treatment Failure Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending this presentation, learners
More informationExpert Perspectives: Best of HCV from EASL 2015
Best of HCV from EASL 2015 Expert Perspectives: Best of HCV from EASL 2015 Saeed Hamid, MD Alex Thompson, MD, PhD This activity is supported by educational grants from AbbVie, Bristol-Myers Squibb, and
More informationAddressing Unmet Medical Needs in HCV Genotype 3
Addressing Unmet Medical Needs in HCV Genotype 3 Karen Doucette, MD, MSc (Epi), FRCPC Associate Professor, Division of Infectious Diseases, Department of Medicine University of Alberta Objectives Identify
More informationVII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES
VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES REGIMENES TERAPÊUTICOS DE LA HEPATITIS C, INTERFERÓN FREE A Coruña 2 Febrero 2013 Rui Sarmento e Castro Centro Hospitalar do Porto HJU ECS Universidade
More informationAssociate Professor of Medicine University of Chicago
Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death
More informationPivotal New England Journal of Medicine papers 2014 Phase 3 Trial data
4 th HCV Therapy Advances Meeting Paris, December 12-13, 14 Pivotal New England Journal of Medicine papers 14 Phase 3 Trial data Stefan Zeuzem, MD University of Frankfurt Germany Disclosures Consultancies:
More informationNew developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
More informationNew York State HCV Provider Webinar Series
New York State HCV Provider Webinar Series Treatment of HCV/HIV Co-Infection Dost Sarpel, MD Division of Infectious Disease Viral Hepatology Milford Regional Medical Center Objectives Review the epidemiology
More informationHIV Infection with HCV Future Directions
HIV Infection with HCV Future Directions Dr Ranjababu (Babu) Kulasegaram Consultant Physician in HIV/GU Medicine Guy s and St Thomas NHS Foundation Trust London, UK Presenter disclosure information Dr
More informationShorter Durations and Pan-genotypic Regimens The Final Frontier. Professor Greg Dore
Shorter Durations and Pan-genotypic Regimens The Final Frontier Professor Greg Dore Disclosures Funding and speaker fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences and Merck Efficacy Evolution
More informationNeed to Assess HCV Resistance to DAAs: Is it Useful and When?
Need to Assess HCV Resistance to DAAs: Is it Useful and When? Stéphane Chevaliez French National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More information4/30/2015. Interactive Case-Based Presentations and Audience Discussion. Debika Bhattacharya, MD, MSc. Learning Objectives
4/3/215 Interactive Case-Based Presentations and Audience Discussion Debika Bhattacharya, MD, MSc Assistant Clinical Professor University of California Los Angeles Los Angeles, California Formatted:4-27-215
More informationHighlights of AASLD 2012 CCO Official Conference Coverage of the 2012 Annual Meeting of the American Association for the Study of Liver Diseases
Highlights of AASLD 12 CCO Official Conference Coverage of the 12 Annual Meeting of the American Association for the Study of Liver Diseases November 9-13, 12 Boston, Massachusetts In partnership with
More informationNEXT GENERATION DIRECT-ACTING ANTIVIRALS
EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN PATIENTS CO-INFECTED WITH HEPATITIS C VIRUS AND HUMAN IMMUNODEFICIENCY VIRUS-1: THE EXPEDITION-2 STUDY J. Rockstroh, K. Lacombe, R. Viani, C. Orkin, D.
More informationCurrent HCV Treatment by Genotype
Current HCV Treatment by Genotype Ari Bunim, MD Assistant Professor Clinical Medicine Weill Cornell Medical College Clinical Director of Hepatology New York-Presbyterian/Queens Objectives To understand
More information6/2/2015. Interactive Case-Based Presentations and Audience Discussion
Interactive Case-Based Presentations and Audience Discussion Arthur Y. Kim, MD Assistant Professor of Medicine Harvard Medical School Director, Viral Hepatitis Clinic Massachusetts General Hospital Boston,
More informationDirect Acting Antivirals for the Treatment of Hepatitis C Infection
Hepatitis C Core Curriculum, Module 2 Direct Acting Antivirals for the Treatment of Hepatitis C Infection Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Objectives Discuss the evolution of hepatitis C treatment
More informationA Practical Approach to HIV/HCV Co-infection
A Practical Approach to HIV/HCV Co-infection Focus on Drug-Drug Interactions Amy Hirsch Shumaker, PharmD, BCPS HIV/Hepatitis C Clinical Pharmacy Specialist Louis Stokes Cleveland VA Medical Center Andrea
More informationSpecial developments in the management of Hepatitis C. Disclosures
Special developments in the management of Hepatitis C Sandeep Mukherjee,MD Division of Gastroenterology CHI Health and Creighton University Medical Center Omaha, NE 68154 Sandeep.Mukherjee@alegent.org
More informationIs HCV drug resistance an issue?
Is HCV drug resistance an issue? 5TH ASIAN CONFERENCE ON HEPATITIS&AIDS NANJING, CHINA 28-29 MAY 2016 FROM BASIC SCIENCE TO CLINICAL PRACTIC Jürgen Kurt Rockstroh Department of Medicine I, University Hospital
More informationHepatitis C Genotypes
9/2/21 OBJECTIVES Project ECHO HCV Collaborative HCV in 21: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationPreliminary Results of an Evaluation of Ledipasvir/Sofosbuvir in Patients with Chronic HCV or HCV/HIV Co-Infection
Preliminary Results of an Evaluation of Ledipasvir/Sofosbuvir in Patients with Chronic HCV or HCV/HIV Co-Infection Konstantin Zhdanov 1, Viacheslav Morozov 2, Elena A Orlova-Morozova 3, Riina Salupere
More information3/28/2016. The Top 5 Things to Remember about Treating HCV
The Top 5 Things to Remember about Treating HCV Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University School of Medicine Durham, North Carolina FORMATTED: MM/DD/YY New York, New York:
More informationReal World Management of HCV in HIV: Approach to Initial Therapy with focus on new DAAs
Real World Management of HCV in HIV: Approach to Initial Therapy with focus on new DAAs Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York Financial Relationships
More information